JSC1

This primary effusion lymphoma (PEL) cell line was established from lymphomatous peritoneal effusion tumor cells that were anaplastic, large, and hematopoietic in appearance. The resultant cell line has a similar morphology, and phenotype with strong CD45 and CD71, partial CD20, and lambda light chain restriction by flow cytometry. JSC-1 is positive for Kaposi?s sarcoma herpesvirus (KSHV) and type 1 Epstein-Barr virus (EBV) by PCR, as is found in other PELs. JSC-1 yields supernatant virions that are highly infectious to primary endothelial cell cultures and exhibits higher basal and induced expression of KSHV lytic cycle gene products than do other previously established PEL cell lines. This dually infected cell line can be employed as an easily controlled and managed system for studying primary infection in vitro and promote the better understanding of the role of KSHV in pathogenesis of certain disease states. Description (Set) Proposed Use (Set) The cell line may be offered as a reagent to the research market.

Inventor(s): Ambinder, Richard

Type of Offer: Licensing



« More Medical Patents

---